Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Kontigo Care AB
With
Uppsala University
The study is a 12-month open-label and randomised comparison between the control group receiving only conventional treatment and the intervention group receiving conventional treatment enhanced with TripleA.
The studies have been designed to reflect as far as possible the conventional care for alcohol dependence. The TripleA product is intended to strengthen the existing methods used during the assessment phase, treatment phase and aftercare of alcohol dependence.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients in care at Addiction and Neuropsychiatry Uppsala University Hospital and at Nämndemansgården Uppsala
18 years or older
Meets at least 2 of the criteria for addiction/substance syndrome according to Diagnostic and statistical manual of mental disorders-5 (DSM-5)
Ability to understand and communicate in Swedish
Ability to handle the technical equipment used in the study (alcoholometer and Smartphone)
Access to a fixed place (living, place for sleeping, place where the phone can be charged
You may not be if
Schizophrenia
Substance syndrome related to other substances than alcohol and nicotin
Lowered lung function (not able to reach acceptable expiration volume for the alcoholometer function)
The patient is taken care of within the frame for The Act on Care of Addicts
Not suitable to participate according to the Investigator
Has not consumed any alcohol during the 4 weeks defined as baseline timeline follow back
Normalized Carbohydrate Deficient Transferrin (CDT) and Phosphatidyl-Ethanol (PEth)-values in blood samples at visit 1
